Freidlin B, McShane LM, Korn EL (2010) Randomized clinical trials with biomarkers: design
issues. J Natl Cancer Inst 102:152–160
Frick KD (2010) Micro-costing quantity data collection methods. Med Care 47:76–81
Fridlyand J et al (2013) Considerations for the successful co-development of targeted cancer
therapies and companion diagnostics. Nat Rev Drug Discov 12(10):743–755
Frueh FW (2013) Regulation, reimbursement, and the long road of implementation of personalized
medicine—a perspective from the United States. Value Health 16(6):S27–S31
Garau M, Towse A, Garrison L et al (2013) Can and should value based pricing be applied to
molecular diagnostics?Pers Med 10:61–72
Garnock-Jones KP, Keating GM, Scott LJ (2010) Trastuzumab: a review of its use as adjuvant
treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
Drugs 70:215–239
Garrison LP, Towse A (2014) Personalized medicine: pricing and reimbursement policies as a
potential barrier to development and adoption, economics of. Encyclopedia of Health Econ,
484–490
Gold MR, Siegel JE, Russell LB et al (1996) Cost-effectiveness in health and medicine. Oxford
University Press, New York
Goldberg P (2009) KRAS finding changes oncology practice but poses profound regulatory
dilemma. Cancer Lett 35:1–8
Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F (2007) Discounting for economic
evaluations: stepping forward toward optimal decision rules. Health Econ 16:307–317
Hamburg MA, Collins FS (2010) The path to personalized medicine. N Engl J Med 363
(4):301–304
Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-
level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736
Hewitt RE (2011) Biobanking: the foundation of personalized medicine. Curr Opin Oncol 23
(1):112–119
Johnson SG, Gruntowicz D, Chua T, Morlock RJ (2015) Financial analysis of CYP2C19
genotyping in patients receiving dual antiplatelet therapy following acute coronary syndrome
and percutaneous coronary intervention. J Manag Care Spec Pharm 21(7):552–557
Kazi DS, Garber AM, Rashmee SU, Adams DA, Mell M (2014) Cost-effectiveness of genotype-
guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med
160:221–232
Lamers LM, McDonnell J, Stalmeier PFM, Krabbe PFM, Busschbach JJV (2006) The Dutch tariff:
results and arguments for an effective design for national EQ-5D valuations studies. Health
Econ 215:1121–1132
Ma Q, Lu AY (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine.
Pharmacol Rev 63(2):437–459
Meckley LM, Neumann PJ (2010) Personalized medicine: factors influencing reimbursement.
Health Policy 94(2):91–100
Merlin T, Farah C, Schubert C, Mitchell A, Hiller JE, Ryan P (2013) Assessing personalized
medicines in Australia: a national framework for reviewing codependent technologies. Med
Decis Making 33:333–342
Mooney G (1989) QALYs: are they enough? A health economist’s perspective. J Med Ethics
15:148–152
National Institute for Health and Clinical Excellence (NICE) (2011) Diagnostics Assessment
Programme manual (DAP), fromhttp://www.nice.org.uk/Media/Default/About/what-we-do/
NICE-guidance/NICE-diagnostics-guidance/Diagnostics-assessment-programme-manual.pdf.
Accessed 13 Sept 2014
National Institute for Health and Clinical Excellence (NICE) (2013) Our guidance.http://www.
nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-
2013-pdf. Accessed 30 Sept 2014
134 A. Bobinac and M. Vehovec